**EriBULin Monotherapy**

**INDICATIONS FOR USE:**

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>*Reimbursement Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.</td>
<td>C50</td>
<td>00228a</td>
<td>ODMS 1/1/2014</td>
</tr>
</tbody>
</table>

*If a reimbursement indicator (e.g. ODMS, CDS) is not defined, the drug and its detailed indication have not been assessed through the formal HSE reimbursement process.

**TREATMENT:**

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 and 8</td>
<td>eriBULin</td>
<td>1.23mg/m²</td>
<td>IV infusion</td>
<td>50-100ml 0.9% sodium chloride over 2-5 minutes</td>
<td>Repeat every 21 days</td>
</tr>
</tbody>
</table>

In the EU the recommended dose refers to the base of the active substance (eriBULin).

Calculation of the individual dose to be administered to a patient must be based on the strength of the ready to use solution that contains 0.44 mg/ml eriBULin and the dose recommendation of 1.23 mg/m².

The dose reduction recommendations shown below are also shown as the dose of eriBULin to be administered based on the strength of the ready to use solution.

In the pivotal EMBRACE trial, the corresponding publication and in some other regions e.g. the US and Switzerland, the recommended dose is based on the salt form (eriBULin mesylate). The equivalent dose of eriBULin mesylate is 1.4mg/m²

EriBULin should not be diluted in 5% glucose.

**ELIGIBILITY:**

- Indications as above
- ECOG 0-2
- Platelets > 100 x 10⁹/L and ANC > 1.5x10⁹/L

**EXCLUSIONS:**

- Hypersensitivity to eriBULin or to any of the excipients
- Breast feeding
- Congenital long QT syndrome

**PRESCRIPTIVE AUTHORITY:**

The treatment plan must be initiated by a Consultant Medical Oncologist
TESTS:
Baseline tests:
- FBC, renal and liver profile
- ECG monitoring if therapy initiated in patients with congestive heart failure, bradyarrhythmias, medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities.

Regular tests:
- FBC, renal and liver profile at the start of each cycle.
- ECG monitoring if clinically indicated as above.

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant.
- The administration of eriBULin should be delayed on day 1 or day 8 for any of the following:
  - ANC < 1 x 10^9/L
  - Platelets < 75 x 10^9/L
  - Grade 3 or 4 non-haematological toxicities
  Thereafter the dose modifications in table 1 apply

Haematological:
Table 1: Dose modification of eriBULin in haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.5 lasting &gt; 7 days</td>
<td></td>
</tr>
<tr>
<td>&lt;1. complicated by fever or infection</td>
<td></td>
</tr>
<tr>
<td>Platelets(x10^9/L)</td>
<td>0.97mg/m²</td>
</tr>
<tr>
<td>&lt; 25</td>
<td></td>
</tr>
<tr>
<td>&lt; 50 complicated by haemorrhage or requiring blood or platelet transfusion</td>
<td></td>
</tr>
<tr>
<td>Reoccurrence of any haematological adverse reactions as specified above</td>
<td></td>
</tr>
<tr>
<td>Despite reduction to 0.97mg/m²</td>
<td>0.62mg/m²</td>
</tr>
<tr>
<td>Despite reduction to 0.62mg/m²</td>
<td>Consider discontinuation</td>
</tr>
</tbody>
</table>

Do not re-escalate the eriBULin dose after it has been reduced.
Renal and Hepatic Impairment:

### Table 2: Dose modification of eriBULin in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cr Cl (ml/min)</td>
<td>Dose</td>
</tr>
<tr>
<td>&lt;50ml/min</td>
<td>Patients may have increased eriBULin exposure and may need a reduction of the dosage. For all patients with renal impairment, caution and close safety monitoring is advised.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Management of adverse events:

### Table 3: Dose Modification of eriBULin for Adverse Events

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3 or 4 non haematological toxicity in previous cycle.</td>
<td>Reduce dose from 1.23mg/m² to 0.97mg/m². If there is any reoccurrence despite the dose reduction, reduce dose further to 0.62mg/m². Do not re-escalate the eriBULin dose after it has been reduced.</td>
</tr>
</tbody>
</table>

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:** Low (Refer to local policy).

**PREMEDICATIONS:** Not usually required

**OTHER SUPPORTIVE CARE:**
- Severe neutropenia may be managed by the use of G-CSF.
- EriBULin may cause adverse reactions such as tiredness and dizziness which may lead to a minor or moderate influence on the ability to drive or use machines. Patients should be advised not to drive or use machines if they feel tired or dizzy.

**ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS**

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Haematology:** Myelosuppression is dose dependent and manifests primarily as neutropenia. Patients experiencing febrile neutropenia, severe neutropenia or thrombocytopenia should be treated according to the recommendations in table 1 above. Patients with ALT or AST >3 x ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia. Although data are limited, patients with bilirubin >1.5 x ULN also have a higher incidence of Grade 4 neutropenia and febrile neutropenia.
- **Peripheral neuropathy:** Patients should be closely monitored for signs of peripheral motor and sensory neuropathy. The development of severe peripheral neurotoxicity requires a delay or reduction

The information contained in this document is a statement of consensus of NCCP and ISMO professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at [http://www.hse.ie/en/Disclaimer](http://www.hse.ie/en/Disclaimer)

**This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemo_regimens

NCCP Chemotherapy Regimen

of dose.

- **QT prolongation:** In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eriBULin concentration, with no QT prolongation observed on Day 1. ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, medicinal products known to prolong the QT interval, including Class la and III anti-arrhythmics, and electrolyte abnormalities. Hypokalemia or hypomagnesemia should be corrected prior to initiating eriBULin and these electrolytes should be monitored periodically during therapy.

**DRUG INTERACTIONS:**

- Risk of drug interactions causing increased concentrations of eriBULin with inhibitors of hepatic transport proteins such as organic anion-transporting proteins (OATPs), P-glycoprotein, multi-drug resistant proteins.
- Possible risk of drug interactions causing decreased concentrations of eriBULin with CYP3A inducers.
- Increased risk of QT prolongation with drugs that disrupt electrolyte levels and Class la and III anti-arrhythmics.
- Current drug interaction databases should be consulted for more information.

**ATC CODE:**

EriBULin - L01XX41

**REFERENCES:**


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20/12/13</td>
<td></td>
<td>Dr Cathy Kelly</td>
</tr>
<tr>
<td>2</td>
<td>15/9/15</td>
<td>Update of dose modification in renal impairment as per change to SmPC</td>
<td>Dr Maccon Keane</td>
</tr>
<tr>
<td>3</td>
<td>4/11/15</td>
<td>Update of indication based on change to SmPC to allow treatment after one previous chemotherapeutic regimen</td>
<td>Dr Maccon Keane</td>
</tr>
<tr>
<td>4</td>
<td>15/11/17</td>
<td>Applied new NCCP regimen template, Updated Title and included equivalent dose of eriBULin mesylate</td>
<td>Prof Maccon Keane</td>
</tr>
</tbody>
</table>

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.
NCCP Chemotherapy Regimen

NCCP Regimen: EriBULin Monotherapy

Published: 10/11/2015
Review: 15/11/2019
Version number: 4
NCCP Regimen Code: 00228

Tumour Group: Breast
ISM0 Contributor: Dr Cathy Kelly, Prof Maccon Keane

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes
Further details on the Cancer Drug Management Programme is available at; http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/